Literature DB >> 12951352

Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.

Stephen H Zinner1, Irene Yu Lubenko, Deborah Gilbert, Kelly Simmons, Xilin Zhao, Karl Drlica, Alexander A Firsov.   

Abstract

OBJECTIVES: According to the mutant selection window (MSW) hypothesis, resistant mutants are selected or enriched at antibiotic concentrations above the MIC but below the mutant prevention concentration (MPC). To test this hypothesis, Streptococcus pneumoniae ATCC 49619 (MIC 0.1 mg/L; MPC 0.5 mg/L) was exposed to moxifloxacin concentrations below the MIC, above the MPC and between the MIC and MPC, i.e. within the MSW.
METHODS: Daily administration of moxifloxacin for 3 consecutive days was mimicked using a two-compartment dynamic model with peripheral units containing a starting inoculum of 10(8) cfu/mL S. pneumoniae. Changes in susceptibility were examined by repeated MIC determinations and by plating the specimens on agar containing zero, 2 x MIC, 4 x MIC and 8 x MIC of moxifloxacin.
RESULTS: Both in terms of the MIC and resistance frequency, S. pneumoniae resistance developed at concentrations that fell inside the MSW [ratios of 24 h area under the curve (AUC24) to MIC between 24 and 47 h]. A Gaussian-like function fitted the AUC24/MIC-dependent increases in MIC and resistance frequency with central points at AUC24/MICs of 38 and 42 h, respectively, where resistant mutants are enriched selectively. Selective enrichment of resistant mutants was not seen at AUC24/MICs <10 h or >100 h.
CONCLUSIONS: These data suggest that AUC24/MICs >100 h may protect against the selection of resistant S. pneumoniae mutants. Since the usual 400 mg dose of moxifloxacin provides much higher AUC24/MIC (270 h), it is expected to prevent mutant selection at clinically achievable concentrations. Also, these data provide further support for the MSW hypothesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951352     DOI: 10.1093/jac/dkg401

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Antibiotic pharmacodynamics and bacterial resistance: usefulness of in vitro models.

Authors:  Stephen H Zinner; Alexander Firsov
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

2.  Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.

Authors:  Aude Ferran; Véronique Dupouy; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

3.  Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.

Authors:  Aude A Ferran; Anne-Sylvie Kesteman; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

Review 4.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.

Authors:  Seung-Jin Lee; Elias Gebru Awji; Na-Hye Park; Seung-Chun Park
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 6.  Is selection relevant in the evolutionary emergence of drug resistance?

Authors:  Troy Day; Silvie Huijben; Andrew F Read
Journal:  Trends Microbiol       Date:  2015-02-11       Impact factor: 17.079

Review 7.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

8.  Moxifloxacin dosing in post-bariatric surgery patients.

Authors:  Pieter Colin; Douglas J Eleveld; Michel M R F Struys; Huybrecht T'Jollyn; Luc M Van Bortel; Johannes Ruige; Jan De Waele; Jan Van Bocxlaer; Koen Boussery
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

Review 9.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.

Authors:  Tomoyuki Homma; Toshihiko Hori; Giichi Sugimori; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.